The European Patent Office (EPO) has published patent application EP4634222A1, detailing an invention by CatalYm GmbH related to an anti-GDF 15 antibody for the neoadjuvant therapy of cancer. The publication includes information on the applicants, inventors, and International Patent Classification (IPC) codes, along with a list of designated European states where patent protection is sought.

This patent publication does not impose immediate regulatory obligations on pharmaceutical companies or drug manufacturers. However, it signifies a step in the patent process for CatalYm GmbH, potentially leading to exclusive rights for their therapeutic antibody. Companies operating in the oncology space should be aware of this publication as it relates to novel cancer treatment modalities.